Pharma bloggers collect their first heads at AZ

Share this article:
Mike Zubillaga is no Dan Rather or Don Imus, but like them, he knows the detrimental impact a band of hostile bloggers can have on one’s job security.

Zubillaga, a regional sales director for oncology at AstraZeneca, became the subject of a “blogswarm” when Pfizer marketer-come-blogger Peter Rost posted an excerpt from an AstraZeneca internal newsletter in which Zubillaga compared performance bonuses to “a big bucket of money sitting in every [doctor’s] office.” Zubillaga also hinted that the company might promote Arimidex against Novartis’ Femara, which would represent a potential violation of AstraZeneca’s 2003 Corporate Integrity Agreement.

Other blogs, like BrandWeek’s BrandWeekNRx and The Star-Ledger’s Pharmalot, picked up the item. When Zubillaga was fired the next day, it was reported in The Philadelphia Inquirer

The news, along with further allegations from Rost’s sources, a group of AstraZeneca employees calling themselves the “Gang of 7,” prompted Rep. Pete Stark to demand an OIG investigation.
 
“Unlike the old news cycle, which had a beginning, middle and end, the online media influence cycle is ongoing,” said Peter Pitts of the Center for Medicine in the Public Interest. “It never sleeps, and rather than burning out, as in olden days, it keeps going, changing form as it progresses. So there’s a need for both constant vigilance and increased engagement, because if you do not act aggressively to influence the information, you have no control.”
Share this article:

Email Newsletters

More in News

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.